Summary:
- This article discusses the critical advancements in the development of mRNA-based vaccines for infectious diseases beyond COVID-19, specifically highlighting progress in clinical trials for malaria and tuberculosis.
- It examines the ongoing challenges researchers face regarding global distribution, thermostability, and the optimization of lipid nanoparticle delivery systems to ensure efficacy in diverse patient populations.